AN2 Therapeutics to Participate at Upcoming Investor Conferences

ANTX 11.14.2024

Full Press ReleaseSEC FilingsOur ANTX Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - 7th Annual Evercore HealthCONx Conference
  • 11.14.2024 - AN2 Therapeutics to Participate at Upcoming Investor Conferences

Recent Filings

  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 14, 2024--AN2 Therapeutics, Inc.(Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December.

Details of the events are as follows:

7thAnnualEvercore HealthCONx Conference,December 3-5, 2024

  • Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview onWednesday, December 4at8:20am ET

Oppenheimer’s Movers in Rare Disease Summit,December 12, 2024

  • Members of management will be available for 1X1 meetings onThursday, December 12, 2024

A webcast of theEvercore HealthCONx Conferencepresentation can be accessed on the Investors section of theAN2 Therapeuticswebsite atwww.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

AboutAN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website atwww.an2therapeutics.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241114578103/en/

COMPANY CONTACT:Lucy O. DayChief Financial Officerl.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:Anne Bowdidgeir@an2therapeutics.com

Source:AN2 Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com